Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Report

Global and Region Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Jul 29, 2022
  • PAGES：207
  • REPORT CODE：GMM880189
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitorsmarket, defines the market attractiveness level of Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors industry, describes the types of Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors market, the applications of major players and the market size, and deeply analyzes the current situation of the global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors market and the development prospects and opportunities of Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors market in Chapter 13.

    By Player:

    • Eli Lilly

    • Janssen Pharmaceuticals

    • AstraZeneca

    • Kotobuki Pharmaceutical

    • Bristol Myers Squibb

    • Boehringer Ingelheim

    • Astellas

    By Type:

    • Invokana (Canagliflozin)

    • Jardiance (Empagliflozin)

    • Farxiga/Forxiga (Dapagliflozin)

    • Suglat (Ipragliflozin)

    By End-User:

    • Hospital

    • Medical Research Institute

    • Other

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Analysis and Outlook to 2022

    • 7.1 Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

    • 7.2 United States Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

    • 7.3 Europe Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

    • 7.4 China Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

    • 7.5 Japan Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

    • 7.6 India Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

    • 7.7 South Korea Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption (2017-2022)

    8 Region and Country-wise Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Analysis and Outlook to 2028

    • 8.1 Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

    • 8.2 United States Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

    • 8.3 Europe Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

    • 8.4 China Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

    • 8.5 Japan Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

    • 8.6 India Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

    • 8.7 South Korea Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast (2022-2028)

    9 Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Outlook by Types and Applications to 2022

    • 9.1 Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Invokana (Canagliflozin) Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Jardiance (Empagliflozin) Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Farxiga/Forxiga (Dapagliflozin) Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Suglat (Ipragliflozin) Consumption and Growth Rate (2017-2022)

    • 9.2 Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Medical Research Institute Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Other Consumption and Growth Rate (2017-2022)

    10 Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Outlook by Types and Applications to 2028

    • 10.1 Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Invokana (Canagliflozin) Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Jardiance (Empagliflozin) Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Farxiga/Forxiga (Dapagliflozin) Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Suglat (Ipragliflozin) Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Medical Research Institute Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Other Consumption Forecast and Growth Rate (2022-2028)

    11 Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Competitive Analysis

    • 14.1 Eli Lilly

      • 14.1.1 Eli Lilly Company Details

      • 14.1.2 Eli Lilly Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Eli Lilly Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Product and Service

    • 14.2 Janssen Pharmaceuticals

      • 14.2.1 Janssen Pharmaceuticals Company Details

      • 14.2.2 Janssen Pharmaceuticals Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Janssen Pharmaceuticals Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Product and Service

    • 14.3 AstraZeneca

      • 14.3.1 AstraZeneca Company Details

      • 14.3.2 AstraZeneca Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 AstraZeneca Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Product and Service

    • 14.4 Kotobuki Pharmaceutical

      • 14.4.1 Kotobuki Pharmaceutical Company Details

      • 14.4.2 Kotobuki Pharmaceutical Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Kotobuki Pharmaceutical Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Product and Service

    • 14.5 Bristol Myers Squibb

      • 14.5.1 Bristol Myers Squibb Company Details

      • 14.5.2 Bristol Myers Squibb Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Bristol Myers Squibb Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Product and Service

    • 14.6 Boehringer Ingelheim

      • 14.6.1 Boehringer Ingelheim Company Details

      • 14.6.2 Boehringer Ingelheim Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Boehringer Ingelheim Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Product and Service

    • 14.7 Astellas

      • 14.7.1 Astellas Company Details

      • 14.7.2 Astellas Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Astellas Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors

    • Figure Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Picture

    • Table Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption by Country (2017-2022)

    • Figure United States Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Table Europe Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure China Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Japan Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure India Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure South Korea Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast by Country (2022-2028)

    • Figure United States Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Invokana (Canagliflozin) Consumption and Growth Rate (2017-2022)

    • Figure Global Jardiance (Empagliflozin) Consumption and Growth Rate (2017-2022)

    • Figure Global Farxiga/Forxiga (Dapagliflozin) Consumption and Growth Rate (2017-2022)

    • Figure Global Suglat (Ipragliflozin) Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Consumption and Growth Rate (2017-2022)

    • Figure Global Medical Research Institute Consumption and Growth Rate (2017-2022)

    • Figure Global Other Consumption and Growth Rate (2017-2022)

    • Figure Global Invokana (Canagliflozin) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Jardiance (Empagliflozin) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Farxiga/Forxiga (Dapagliflozin) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Suglat (Ipragliflozin) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Medical Research Institute Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Other Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Export by Region (Top 5 Countries) (2017-2028)

    • Table Eli Lilly (Foundation Year, Company Profile and etc.)

    • Table Eli Lilly Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

    • Table Eli Lilly Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Product and Service

    • Table Janssen Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Janssen Pharmaceuticals Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

    • Table Janssen Pharmaceuticals Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Product and Service

    • Table AstraZeneca (Foundation Year, Company Profile and etc.)

    • Table AstraZeneca Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

    • Table AstraZeneca Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Product and Service

    • Table Kotobuki Pharmaceutical (Foundation Year, Company Profile and etc.)

    • Table Kotobuki Pharmaceutical Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

    • Table Kotobuki Pharmaceutical Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Product and Service

    • Table Bristol Myers Squibb (Foundation Year, Company Profile and etc.)

    • Table Bristol Myers Squibb Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bristol Myers Squibb Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Product and Service

    • Table Boehringer Ingelheim (Foundation Year, Company Profile and etc.)

    • Table Boehringer Ingelheim Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

    • Table Boehringer Ingelheim Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Product and Service

    • Table Astellas (Foundation Year, Company Profile and etc.)

    • Table Astellas Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Price, Value and Gross Profit (2017-2022)

    • Table Astellas Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US